Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 (anti-PD-L1 ADC) + serplulimab in advanced lung cancer
CTR20254515Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43, serplulimab in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by HyBioPharma. Started Feb 2026; status: active.
02
Drugs
HLX43serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20254515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254515.